Differential expression of cell cycle regulators in HCV-infection and related hepatocellular carcinoma

World Journal of Hepatology

Volumn 2, Issue 1, 2010, Pages 32-41

  El Bassiouny, Azza E ^a   Nosseir, Mona M ^b   Zoheiry, Mona K ^a   Ameen, Noha A ^b   Abdel Hadi, Ahmed M ^b   Ibrahim, Ibrahim M ^b   Zada, Suher ^c   El Deen, Abdel Hakeem Saad ^d   El Bassiouni, Nora E ^b  

^a Giza   (Egypt)

^b THEODOR BILHARZ RESEARCH INSTITUTE   (Egypt)

^c AMERICAN UNIVERSITY IN CAIRO   (Egypt)

^d CAIRO UNIVERSITY   (Egypt)

Author keywords

Cell cycle; Chronic hepatitis C; Cyclin D1; Cyclin E; Hepatocellular carcinoma; Liver cirrhosis; P21; p27; Rb p105

Indexed keywords

EID: 79961129699     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v2.i1.32     Document Type: Article

References (58)

1. Owa T, Yoshino H, Yoshimatsu K, Nagasu T. Cell cycleregulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents. Curr Med Chem 2001; 8: 1487-1503
2. Morgan DO. The cell cycle control system. In: E Lawrence. The Cell Cycle: Principles of control. London: New Science press Ltd, 2007: 29-55
3. Bornfeldt KE. The cyclin-dependent kinase pathway moves forward. Circ Res 2003; 92: 345-347
4. Rosania GR, Chang YT. Targeting hyperproliferative disorders with cyclin dependent kinase inhibitors. Expert Opinion on Therapeutic Patents 2000; 10: 215-230. Available from: URL: http://www.Informapharmascience.com/ddi. Drug development and industrial pharmacy
5. Jung YJ, Lee KH, Choi DW, Han CJ, Jeong SH, Kim KC, Oh JW, Park TK, Kim CM. Reciprocal expressions of cyclin E and cyclin D1 in hepatocellular carcinoma. Cancer Lett 2001; 168: 57-63
6. Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP. Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur J Cancer 2007; 43: 979-992
7. Nan KJ, Jing Z, Gong L. Expression and altered subcellular localization of the cyclin-dependent kinase inhibitor p27Kip1 in hepatocellular carcinoma. World J Gastroenterol 2004; 10: 1425-1430
8. Polak J, Pekova S, Schwarz J, Kozak T, Haskovec C. Expression of cyclin-dependent kinase inhibitors in leukemia. Cas Lek Cesk 2003; 142: 25-28
9. Baldi A, Esposito V, De Luca A, Howard CM, Mazzarella G, Baldi F, Caputi M, Giordano A. Differential expression of the retinoblastoma gene family members pRb/p105, p107, and pRb2/p130 in lung cancer. Clin Cancer Res 1996; 2: 1239-1245
10. Nevins JR. Toward an understanding of the functional complexity of the E2F and retinoblastoma families. Cell Growth Differ 1998; 9: 585-593
11. Sanseverino F, Torricelli M, Petraglia F, Giordano A. Role of the retinoblastoma family in gynecological cancer. Cancer Biol Ther 2003; 2: 636-641
12. Lü ZL, Luo DZ, Wen JM. Expression and significance of tumor-related genes in HCC. World J Gastroenterol 2005; 11: 3850-3854
13. Lake-Bakaar G, Mazzoccoli V, Ruffini L. Digital image analysis of the distribution of proliferating cell nuclear antigen in hepatitis C virus-related chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Dig Dis Sci 2002; 47: 1644-1648
14. Miura N, Horikawa I, Nishimoto A, Ohmura H, Ito H, Hirohashi S, Shay JW, Oshimuraa M. Progressive telomere shortening and telomerase reactivation during hepatocellular carcinogenesis. Cancer Genet Cytogenet 1997; 93: 56-62
15. Marshall A, Rushbrook S, Davies SE, Morris LS, Scott IS, Vowler SL, Coleman N, Alexander G. Relation between hepatocyte G1 arrest, impaired hepatic regeneration, and fibrosis in chronic hepatitis C virus infection. Gastroenterology 2005; 128: 33-42
16. Flemington EK. Herpesvirus lytic replication and the cell cycle: arresting new developments. J Virol 2001; 75: 4475-4481
17. Krtolica A, Parrinello S, Lockett S, Desprez PY, Campisi J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc Natl Acad Sci USA 2001; 98: 12072-12077
18. Hodinka RL. Detection of HCV RNA in serum by reverse transcriptase-PCR and radiolabeled liquid hybridization. Method Mol Med 1998; 19: 29-45
19. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994; 20: 15-20
20. Colecchia A, Scaioli E, Vestito A, Grazi GL, Festi D. Tumor grading of hepatocellular carcinoma by preoperative needle biopsy: Is it useful for choosing the best therapeutic strategy? Dig Liver Dis 2009; 41: A18
21. Khan AA, Abel PD, Chaudhary KS, Gulzar Z, Stamp GW, Lalani EN. Inverse correlation between high level expression of cyclin E and proliferation index in transitional cell carcinoma of the bladder. Mol Pathol 2003; 56: 353-361
22. Peng SY, Chou SP, Hsu HC. Association of downregulation of cyclin D1 and of overexpression of cyclin E with p53 mutation, high tumor grade and poor prognosis in hepatocellular carcinoma. J Hepatol 1998; 29: 281-289
23. Zhou Q, He Q, Liang LJ. Expression of p27, cyclin E and cyclin A in hepatocellular carcinoma and its clinical significance. World J Gastroenterol 2003; 9: 2450-2454
24. Lindahl T, Landberg G, Ahlgren J, Nordgren H, Norberg T, Klaar S, Holmberg L, Bergh J. Overexpression of cyclin E protein is associated with specific mutation types in the p53 gene and poor survival in human breast cancer. Carcinogenesis 2004; 25: 375-380
25. Crary GS, Albrecht JH. Expression of cyclin-dependent kinase inhibitor p21 in human liver. Hepatology 1998; 28: 738-743
26. Armengol C, Boix L, Bachs O, Sole M, Fuster J, Sala M, Llovet JM, Rodes J, Bruix J. p27(Kip1) is an independent predictor of recurrence after surgical resection in patients with small hepatocellular carcinoma. J Hepatol 2003; 38: 591-597
27. Santopietro R, Shabalova I, Petrovichev N, Kozachenko V, Zakharova T, Pajanidi J, Podistov J, Chemeris G, Sozaeva L, Lipova E, Tsidaeva I, Ivanchenko O, Pshepurko A, Zakharenko S, Nerovjna R, Kljukina L, Erokhina O, Branovskaja M, Nikitina M, Grunberga V, Grunberg A, Juschenko A, Cintorino M, Tosi P, Syrjänen K, Syrjänen S. Cell cycle regulators p105, p107, Rb2/p130, E2F4, p21CIP1/ WAF1, cyclin A in predicting cervical intraepithelial neoplasia, high-risk human papillomavirus infections and their outcome in women screened in three new independent states of the former Soviet Union. Cancer Epidemiol Biomarkers Prev 2006; 15: 1250-1256
28. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Semin Liver Dis 1995; 15: 64-69
29. Bruno S, Silini E, Crosignani A, Borzio F, Leandro G, Bono F, Asti M, Rossi S, Larghi A, Cerino A, Podda M, Mondelli MU. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: A prospective study. Hepatology 2003; 25: 754-758
30. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minireview: Cyclin D1: normal and abnormal functions. Endocrinology 2004; 145: 5439-5447
31. Nishida N, Fukuda Y, Komeda T, Kita R, Sando T, Furukawa M, Amenomori M, Shibagaki I, Nakao K, Ikenaga M. Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res 1994; 54: 3107-3110
32. Masaki T, Shiratori Y, Rengifo W, Igarashi K, Yamagata M, Kurokohchi K, Uchida N, Miyauchi Y, Yoshiji H, Watanabe S, Omata M, Kuriyama S. Cyclins and cyclin-dependent kinases: comparative study of hepatocellular carcinoma versus cirrhosis. Hepatology 2003; 37: 534-543
33. Donnellan R, Chetty R. Cyclin E in human cancers. FASEB J 1999; 13: 773-780
34. Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M, Herliczek TW, Bacus SS. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002; 347: 1566-1575
35. Shi YZ, Hui AM, Takayama T, Li X, Cui X, Makuuchi M. Reduced p21WAF1/CIP1 protein expression is predominantly related to altered p53 in hepatocellular carcinomas. British J Cancer 2000; 83: 50-55.
36. Fredersdorf S, Milne AW, Hall PA, Lu X. Characterizationof a panel of novel anti-p21Waf1/Cip1 monoclonal antibodies and immunochemical analysis of p21Waf1/Cip1 expression in normal human tissues. Am J Pathol 1996; 148: 825-835
37. Wagayama H, Shiraki K, Yamanaka T, Sugimoto K, Ito T, Fujikawa K, Takase K, Nakano T. p21WAF1/CTP1 expression and hepatitis virus type. Dig Dis Sci 2001; 46: 2074-2079
38. Kobayashi S, Matsushita K, Saigo K, Urashima T, Asano T, Hayashi H, Ochiai T. P21WAF1/CIP1 messenger RNA expression in hepatitis B, C virus-infected human hepatocellular carcinoma tissues. Cancer 2001; 91: 2096-2103
39. Chang BD, Watanabe K, Broude EV, Fang J, Poole JC, Kalinichenko TV, Roninson IB. Effects of p21Waf1/ Cip1/Sdi1 on cellular gene expression: implications for carcinogenesis, senescence, and age-related diseases. Proc Natl Acad Sci USA 2000; 97: 4291-4296
40. Wagayama H, Shiraki K, Sugimoto K, Ito T, Fujikawa K, Yamanaka T, Takase K, Nakano T. High expression of p21WAF1/CIP1 is correlated with human hepatocellular carcinoma in patients with hepatitis C virus-associated chronic liver diseases. Hum Pathol 2002; 33: 429-434
41. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366: 701-704
42. Kao JT, Chuah SK, Huang CC, Chen CL, Wang CC, Hung CH, Chen CH, Wang JH, Lu SN, Lee CM, Changchien CS, Hu TH. P21/WAF1 is an independent survival prognostic factor for patients with hepatocellular carcinoma after resection. Liver Int 2007; 27: 772-781
43. Furutani M, Arii S, Tanaka H, Mise M, Niwano M, Harada T, Higashitsuji H, Imamura M, Fujita J. Decreased expression and rare somatic mutation of the CIP1/WAF1 gene in human hepatocellular carcinoma. Cancer Lett 1997; 111: 191-197
44. Di Leonardo A, Linke SP, Clarkin K, Wahl GM. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev 1994; 8: 2540-2551
45. Gartel AL, Serfas MS, Tyner AL. p21--negative regulator of the cell cycle. Proc Soc Exp Biol Med 1996; 213: 138-149
46. Pellegata NS, Antoniono RJ, Redpath JL, Stanbridge EJ. DNA damage and p53-mediated cell cycle arrest: a reevaluation. Proc Natl Acad Sci USA 1996; 93: 15209-15214
47. Fotedar R, Fitzgerald P, Rousselle T, Cannella D, Dorée M, Messier H, Fotedar A. p21 contains independent binding sites for cyclin and cdk2: both sites are required to inhibit cdk2 kinase activity. Oncogene 1996; 12: 2155-2164
48. Matsuda Y, Ichida T, Genda T, Yamagiwa S, Aoyagi Y, Asakura H. Loss of p16 contributes to p27 sequestration by cyclin D(1)-cyclin-dependent kinase 4 complexes and poor prognosis in hepatocellular carcinoma. Clin Cancer Res 2003; 9: 3389-3396
49. Matsuda Y. Molecular mechanism underlying the functional loss of cyclindependent kinase inhibitors p16 and p27 in hepatocellular carcinoma. World J Gastroenterol 2008; 14: 1734-1740
50. Jing Z, Nan KJ, Hu ML. Cell proliferation, apoptosis and the related regulators p27, p53 expression in hepatocellular carcinoma. World J Gastroenterol 2005; 11: 1910-1916
51. Lei PP, Zhang ZJ, Shen LJ, Li JY, Zou Q, Zhang HX. Expression and hypermethylation of p27 kip1 in hepatocarcinogenesis. World J Gastroenterol 2005; 11: 4587-4591
52. Shehata MA, Nosseir HR, Nagy HM, Farouk G. Cyclin dependent kinase inhibitor p27(kip1) expression and subcellular localization in relation to cell proliferation in hepatocellualr carcinoma. Egypt J Immunol 2006; 13: 115-130
53. Filipits M, Puhalla H, Wrba F. Low p27Kip1 expression is an independent prognostic factor in gallbladder carcinoma. Anticancer Res 2003; 23: 675-679
54. Sgambato A, Ratto C, Faraglia B, Merico M, Ardito R, Schinzari G, Romano G, Cittadini AR. Reduced expression and altered subcellular localization of the cyclin-dependent kinase inhibitor p27(Kip1) in human colon cancer. Mol Carcinog 1999; 26: 172-179
55. Beijersbergen RL, Bernards R. Cell cycle regulation by the retinoblastoma family of growth inhibitory proteins. Biochim Biophys Acta 1996; 1287: 103-120
56. Classon M, Harlow E. The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer 2002; 2: 910-917
57. Bagui TK, Mohapatra S, Haura E, Pledger WJ. P27Kip1 and p21Cip1 are not required for the formation of active D cyclin-cdk4 complexes. Mol Cell Biol 2003; 23: 7285-7290
58. Yonemura Y, Ohoyama S, Kimura H, Kamata T, Matsumoto H, Yamaguchi A, Kosaka T, Miwa K, Miyazaki I. The expression of proliferative-associated nuclear antigen p105 in gastric carcinoma. Cancer 1991; 67: 2523-2528